Literature DB >> 17420249

Phosphorylated galectin-3 mediates tumor necrosis factor-related apoptosis-inducing ligand signaling by regulating phosphatase and tensin homologue deleted on chromosome 10 in human breast carcinoma cells.

Nachman Mazurek1, Yun Jie Sun, Kai-Feng Liu, Michael Z Gilcrease, Wendy Schober, Pratima Nangia-Makker, Avraham Raz, Robert S Bresalier.   

Abstract

Galectin-3 (GAL3), a beta-galactoside-binding lectin, confers chemoresistance to a wide variety of cancer cell types. It may exhibit anti- or pro-apoptotic activity depending on the nature of the stimulus. We report here that introducing phosphorylated galectin-3 (P-GAL3) into GAL3-null, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant human breast carcinoma cells promotes TRAIL-induced apoptotic cell death by stimulating the phosphorylation/inactivation of the pro-apoptotic molecule Bad resulting in the inhibition of mitochondrial depolarization and the release of cytochrome c. Exposure of the transfectant cells to TRAIL leads to the recruitment of the initiator capase-8 followed by activation of the effector caspase-9, independent of cytochrome c, and subsequently the processing of the executioner caspase-3. P-GAL3 and phosphatase and tensin homologue deleted on chromosome 10 (PTEN) were coordinately expressed, with concomitant dephosphorylation of Akt in TRAIL-sensitive cells. In contrast, overexpression of phospho-mutant GAL3 (incapable of phosphorylation) failed to elicit similar responses. Depletion of PTEN using small interference RNAs reinstated Akt phosphorylation and conferred TRAIL resistance. In addition phosphatidylinositol 3-kinase inhibitors rendered the phospho-mutant GAL3-resistant cells sensitive to TRAIL. These findings suggest a pivotal role for P-GAL3 in promoting TRAIL sensitivity through activation of a nonclassic apoptotic pathway and identify P-GAL3 as a novel regulator of PTEN.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17420249     DOI: 10.1074/jbc.M608810200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells.

Authors:  N Mazurek; J C Byrd; Y Sun; M Hafley; K Ramirez; J Burks; R S Bresalier
Journal:  Cell Death Differ       Date:  2011-09-23       Impact factor: 15.828

2.  Transient gene silencing of galectin-3 suppresses pancreatic cancer cell migration and invasion through degradation of β-catenin.

Authors:  Tsutomu Kobayashi; Tatsuo Shimura; Toshiki Yajima; Norio Kubo; Kenichiro Araki; Soichi Tsutsumi; Hideki Suzuki; Hiroyuki Kuwano; Avraham Raz
Journal:  Int J Cancer       Date:  2011-03-29       Impact factor: 7.396

3.  A galectin-3 sequence polymorphism confers TRAIL sensitivity to human breast cancer cells.

Authors:  Nachman Mazurek; James C Byrd; Yunjie Sun; Suguru Ueno; Robert S Bresalier
Journal:  Cancer       Date:  2011-03-28       Impact factor: 6.860

Review 4.  Breast cancer proteome takes more than two to tango on TRAIL: beat them at their own game.

Authors:  Ammad Ahmad Farooqi; Sundas Fayyaz; Muhammad Tahir; Muhammed Javed Iqbal; Shahzad Bhatti
Journal:  J Membr Biol       Date:  2012-08-17       Impact factor: 1.843

5.  Tyrosine-phosphorylated galectin-3 protein is resistant to prostate-specific antigen (PSA) cleavage.

Authors:  Vitaly Balan; Pratima Nangia-Makker; Dhong Hyo Kho; Yi Wang; Avraham Raz
Journal:  J Biol Chem       Date:  2012-01-09       Impact factor: 5.157

6.  Transient silencing of galectin-3 expression promotes both in vitro and in vivo drug-induced apoptosis of human pancreatic carcinoma cells.

Authors:  Tsutomu Kobayashi; Tatsuo Shimura; Toshiki Yajima; Norio Kubo; Kenichiro Araki; Wataru Wada; Soichi Tsutsumi; Hideki Suzuki; Hiroyuki Kuwano; Avraham Raz
Journal:  Clin Exp Metastasis       Date:  2011-02-18       Impact factor: 5.150

Review 7.  Glycobiology of cell death: when glycans and lectins govern cell fate.

Authors:  R G Lichtenstein; G A Rabinovich
Journal:  Cell Death Differ       Date:  2013-05-24       Impact factor: 15.828

8.  Inhibition of metastatic tumor formation in vivo by a bacteriophage display-derived galectin-3 targeting peptide.

Authors:  Jessica R Newton-Northup; Marie T Dickerson; Lixin Ma; Cynthia L Besch-Williford; Susan L Deutscher
Journal:  Clin Exp Metastasis       Date:  2012-08-01       Impact factor: 5.150

Review 9.  The role of galectin-3 in cancer drug resistance.

Authors:  Tomoharu Fukumori; Hiro-Omi Kanayama; Avraham Raz
Journal:  Drug Resist Updat       Date:  2007-06-04       Impact factor: 18.500

10.  Galectin-3 gene silencing inhibits migration and invasion of human tongue cancer cells in vitro via downregulating β-catenin.

Authors:  Dong Zhang; Zheng-gang Chen; Shao-hua Liu; Zuo-qing Dong; Martin Dalin; Shi-san Bao; Ying-wei Hu; Feng-cai Wei
Journal:  Acta Pharmacol Sin       Date:  2012-10-29       Impact factor: 7.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.